Table 2.
Characteristics of 3479 patients with known SF3B1 mutation status within the IWG data set
| Variable | SF3B1 WT | SF3B1 mutated | P |
|---|---|---|---|
| Number of patients | 2684 | 795 | |
| Sex | |||
| Female | 978 (36) | 349 (44) | <.001 |
| Male | 1706 (64) | 446 (56) | |
| Age (y) at sample, median (range) | 69 (18-99) | 72 (34-94) | <.001 |
| <40 | 61 (2) | 3 (<1) | <.001 |
| 40-49 | 131 (5) | 22 (3) | |
| 50-59 | 326 (12) | 78 (10) | |
| 60-69 | 822 (31) | 205 (26) | |
| 70-79 | 959 (36) | 348 (44) | |
| 80-89 | 313 (12) | 125 (16) | |
| ≥90 | 15 (1) | 6 (1) | |
| Unknown | 57 (2) | 8 (1) | |
| WHO 2008 | |||
| Del(5q) | 91 (3) | 20 (3) | <.001 |
| RARS | 60 (2) | 273 (34) | |
| RA/RCUD | 238 (9) | 21 (3) | |
| RCMD | 520 (19) | 18 (2) | |
| RCMD-RS | 56 (2) | 171 (22) | |
| RAEB-1 | 412 (15) | 49 (6) | |
| RAEB-2 | 426 (16) | 28 (4) | |
| Unknown | 735 (27) | 206 (26) | |
| FAB | |||
| RA | 611 (23) | 61 (8) | <.001 |
| RARS | 103 (4) | 352 (44) | |
| RAEB | 763 (28) | 86 (11) | |
| RAEB-T | 48 (2) | 5 (1) | |
| CMML | 61 (2) | 4 (1) | |
| Unknown | 1098 (41) | 287 (36) | |
| Blast %, median (IQR) | 4.0 (1, 9.0) | 2.0 (1.0, 4.0) | <.001 |
| <5 | 1347 (50) | 635 (80) | <.001 |
| 5-10 | 649 (24) | 94 (12) | |
| 11-20 | 486 (18) | 33 (4) | |
| 21-30 | 23 (1) | 2 (<1) | |
| Unknown | 179 (7) | 31 (4) | |
| Hemoglobin (g/dL), median (IQR) | 9.9 (8.7, 11.3) | 9.5 (8.6, 10.5) | <.001 |
| <8.0 | 307 (11) | 102 (13) | 0.001 |
| 8.0-9.99 | 1000 (37) | 353 (44) | |
| 10.0-11.99 | 774 (29) | 249 (31) | |
| ≥12.0 | 447 (17) | 34 (4) | |
| Unknown | 156 (6) | 57 (7) | |
| ANC (×109/L), median (IQR) | 1.6 (0.8, 3.3) | 2.73 (1.7, 4.24) | <.001 |
| <0.5 | 262 (10) | 20 (3) | <.001 |
| 0-5 to 0.99 | 393 (15) | 43 (5) | |
| 1.0-1.8 | 415 (15) | 96 (12) | |
| ≥1.8 | 940 (35) | 410 (52) | |
| Unknown | 674 (25) | 226 (28) | |
| Platelets (×109/L), median (IQR) | 93 (48, 171) | 261 (150, 378) | <.001 |
| <50 | 639 (24) | 41 (5) | <.001 |
| 50-100 | 668 (25) | 60 (8) | |
| 100- 149 | 410 (15) | 76 (10) | |
| 150-449 | 662 (25) | 422 (53) | |
| ≥450 | 74 (3) | 118 (15) | |
| Unknown | 231 (9) | 78 (10) | |
| IPSS-R | |||
| Very low | 263 (10) | 152 (19) | <.001 |
| Low | 610 (23) | 352 (44) | |
| Intermediate | 531 (20) | 86 (11) | |
| High | 391 (14) | 45 (6) | |
| Very high | 320 (12) | 9 (1) | |
| Unknown | 569 (21) | 151 (19) | |
| IPSS-R cytogenetic risk | |||
| Very good | 79 (3) | 38 (5) | <.001 |
| Good | 1681 (63) | 608 (76) | |
| Intermediate | 322 (12) | 93 (12) | |
| Poor | 154 (6) | 14 (2) | |
| Very poor | 271 (10) | 7 (1) | |
| Unknown | 177 (7) | 35 (4) |
Values are reported as n (%) of patients unless otherwise indicated.
ANC, absolute neutrophil count; CMML, chronic myelomonocytic leukemia; IPSS-R, revised International Prognostic Scoring System; IQR, interquartile range; RA, refractory anemia; RAEB, refractory anemia with excess blasts; RAEB-T, RAEB in transformation; WT, wild-type.